Dinutuximab

Generic Name
Dinutuximab
Brand Names
Unituxin, Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)
Drug Type
Biotech
Chemical Formula
-
CAS Number
1363687-32-4
Unique Ingredient Identifier
7SQY4ZUD30
Background

Dinutuximab is an IgG1 monoclonal human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant region...

Indication

Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen ...

Associated Conditions
High Risk Neuroblastoma
Associated Therapies
-
Clinical Trials
Related News
consultancy.asia
·

China's National Reimbursement Drug List (NRDL) outlook for 2024

The National Reimbursement Drug List (NRDL) faces budget pressure and competition, with 445 drugs passing formal review in 2024. Oncology, immunology, neurology, and rare diseases see strategic positioning and comparator choices as key. Contract renewals and re-negotiations are under pressure, emphasizing clear messaging and data preparation for NRDL success.
ir.unither.com
·

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

United Therapeutics reports Q3 2024 revenue of $748.9M, up 23% YoY. CEO Martine Rothblatt highlights a $3B annual revenue run rate and upcoming clinical data reads. President Michael Benkowitz notes increasing demand for products serving pulmonary hypertension and high-risk neuroblastoma patients. Key financial highlights include net income of $309.1M and diluted EPS of $6.39.
stjude.org
·

Strength in numbers: Cooperative group clinical trials move the needle against pediatric cancer

Childhood cancer research requires collaboration among multidisciplinary investigators, with patients and families also playing crucial roles. Neuroblastoma, a common solid tumor in children, necessitates novel therapies despite improvements in survival rates. Clinical trials, led by organizations like the Children's Oncology Group and New Approaches to Neuroblastoma Therapy consortium, aim to develop new treatments and biomarkers, demonstrating the importance of cooperative groups in advancing pediatric cancer research.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy